Agendia Announces Six Studies in Breast and Colon Cancer for Presentation at 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)

Amsteram and Irvine, California (ots/PRNewswire) -

Agendia, a commercial-stage molecular cancer diagnostics company,
announces today that it will present results from four completed and
one ongoing study, at the Annual Meeting of the American Society of
Clinical Oncology (ASCO). Agendia will publish the results of an
additional study in conjunction with the event. The meeting will be
held from 3-7 June, 2011 at McCormick Place in Chicago, IL.

Currently on the market in US and Europe, Agendia's Symphony(TM)
suite of molecular diagnostic breast cancer tests enables physicians
to determine whether a given breast cancer patient is likely to
benefit from hormonal therapy, chemotherapy and targeted therapies,
thereby providing benefits over existing treatment approaches for
patients, physicians and payors.

Agendia's lead product, Mammaprint(R), is currently the only
molecular diagnostic breast cancer recurrence test available on the
market to have received FDA clearance. Agendia's product development
pipeline includes a further extension of its breast cancer tests as
well as similar molecular diagnostic products for colon cancer.

All of the abstracts listed below can currently be found online
at http://www.ASCO.org. Presentation details are as follows (all
times are in Central Time).

Monday, June 6, 2011

Breast Cancer

1. Poster Presentation: Combined use of MammaPrint(R) and
Molecular Subtyping Profile (BluePrint(TM)) identifies subgroups with
marked differences in response to neo-adjuvant treatment.

- Lead Author: F. de Snoo, P. Roepman, O. Krijgsman, R.A. Bender,
R. Bernards, A. Glas

- Presentation Time: 8:00 AM - 12:00 PM; Location: Hall A

2. Poster Presentation: A gene profile that identifies molecular
subtypes of breast cancer is highly enriched in genes having Estrogen
Receptor binding sites.

- Lead Author: W. Zwart, F. De Snoo, O. Krijgsman, P. Roepman, S.
Tian, A. Glas, R.A. Bender, J. Carroll, R. Bernards

- Presentation Time: 1:00 PM - 5:00 PM; Location: Hall A

3. Poster Presentation: Correlation between miRNA and gene
expression profiles and response to neoadjuvant chemotherapy in
patients with locally advanced and inflammatory breast cancer.

- Lead Author: G. Somlo, S. M. Li, X. Wu, S. Lau, P. H. Frankel,
L. Kruper, H. Gao, G. Sun, J.H. Yim, A. Hurria, J. E. Mortimer, F. De
Snoo, I.B. Paz, J. Rossi, E. Wang, P. Roepman, Y. Yen, L. van't Veer,
R. A. Bender

- Presentation Time: 1:00 PM - 5:00 PM; Location: Hall A

4. Publication-only Abstract: Comparison of MammaPrint(R) and
TargetPrint(R) with clinical parameters in patients with breast
cancer: Findings from a prospective U.S. cohort.

- Lead Author: K. B. Deck, R. Sinha, D. Kerlin, J. Barone, E.
Rivera, A. A. Garcia, K. Yao, L. Stork-Sloots, R. A. Bender, B.
Nguyen

Colorectal Cancer

5. Poster Presentation: The PARSC trial, a prospective study for
the assessment of recurrence risk in stage II colon cancer (CC)
patients using ColoPrint(R).

- Lead Author: Salazar R, Rosenberg R, Lutke Holzik M, Marshall
J, van der Hoeven K, Glimelius B, Bibeau, F.

- Presentation Time: 8:00 AM - 12:00 PM; Location: Hall A

6. Poster Presentation & Discussion: The role of activating
mutations of KRAS, BRAF, and PIK3CA pathway convergence at the
transcriptional level and prediction of treatment response to
cetuximab in colorectal cancer.

- Lead Author: I. Simon, S. Tian, V. Moreno, P. Roepman, J.
Tabernero, M. Snel, T. Macarulla, L. van't Veer, R. Bernards, G.
Capella

- Presentation Time: 8:00 AM - 12:00 PM; Discussion Time: 11:30
AM to 12:30 PM; Location: Hall D1

About Agendia

Agendia is an innovative molecular diagnostic company, striving
to bring more effective, individualized treatments within reach of
patients. Building on a genomics platform for tumour gene expression
profiling, the company's tests help physicians more accurately select
a course of cancer treatment for their patients. Agendia markets four
products, with several new genomic tests under development. In
addition, Agendia collaborates with pharmaceutical companies to
develop companion diagnostic tests in the area of oncology. Agendia
is based in Amsterdam, the Netherlands and in Irvine, California. For
more information, please visit http://www.agendia.com.

For further information, please contact:
Agendia
Dr. Bernhard Sixt, President & CEO
Investorrelations@agendia.com
International media and investor enquiries
M:Communications
Mary-Jane Elliott / Emma Thompson
Tel: +44(0)20-7920-2345, E-mail: Agendia@mcomgroup.com
Dutch media enquiries
Huijskens Communications
Ian Bickerton
Tel: +31(0)20-685-5955, E-mail: i.bickerton@huijskens.nl
US Media enquiries
Ricochet Public Relations
Valerie Carter
Tel: +1-202-316-0143, E-mail: vcarter@ricochetpr.com

ots Originaltext: Agendia BV
Im Internet recherchierbar: http://www.presseportal.de

Contact:
.